| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 13,250 | 8,672 |
| Depreciation of leasehold improvements and equipment | 473 | 316 |
| Amortization of intangibles | 113 | 75 |
| Noncash lease expense | 496 | 332 |
| Share-based compensation expense | 4,319 | 2,563 |
| Loss (gain) on disposal of leasehold improvements and equipment | -4 | -4 |
| (recovery of) / allowance for credit losses | -1,244 | -1,232 |
| Non-cash financing costs | -41 | -26 |
| Trade receivables | -506 | 656 |
| Inventories | 9,599 | 5,214 |
| Implementation costs for cloud computing arrangement | 66 | 66 |
| Prepaid expenses and other assets | -375 | -288 |
| Accounts payable | 4,216 | 5,154 |
| Accrued expenses | 883 | -436 |
| Deferred revenue | 95 | 95 |
| Customer deposits and other | -324 | -308 |
| Operating lease liabilities | -713 | -480 |
| Net cash provided by operating activities | 12,825 | 9,133 |
| Purchases of leasehold improvements and equipment | 191 | 167 |
| Proceeds from the sale of leasehold improvements and equipment, net | 0 | - |
| Net cash used in investing activities | -191 | -167 |
| Proceeds from exercise of stock options | 7,018 | 6,866 |
| Payment of debt issuance costs | 12 | 12 |
| Principal payments on finance leases | 10 | 6 |
| Net cash provided by financing activities | 6,996 | 6,848 |
| Net increase in cash and cash equivalents | 19,630 | 15,814 |
| Cash and cash equivalents at beginning of period | 44,660 | - |
| Cash and cash equivalents at end of period | 64,290 | - |
Niagen Bioscience, Inc. (NAGE)
Niagen Bioscience, Inc. (NAGE)